Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.66 |
| ▸ | HTR2B | P41595 | 1/20 | 0.66 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 1/20 | 0.51 |
| ▸ | MTNR1A | P48039 | 4/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.50 |
| ▸ | NQO2 | P16083 | 3/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12593301 | 1.00 | HTR2C (0.66) | HTR2CHTR2AHTR2BCYP19A1CYP11B1 | |
| SCHEMBL13306294 | 1.00 | HTR2C (0.66) | HTR2CHTR2AHTR2BCYP19A1CYP11B1 | |
| SCHEMBL13306289 | 0.89 | HTR2C (0.62) | HTR2CHTR2AHTR2BCYP19A1CYP11B1 | |
| SCHEMBL6797994 | 0.89 | HTR2C (0.62) | HTR2CHTR2AHTR2BCYP19A1CYP11B1 | |
| SCHEMBL2970487 | 0.89 | HTR2C (0.62) | HTR2CHTR2AHTR2BCYP19A1CYP11B1 | |
| SCHEMBL8068811 | 0.85 | HTR2C (0.64) | HTR2CHTR2AHTR2BCYP19A1DRD2 | |
| SCHEMBL16944438 | 0.85 | HTR2C (0.64) | HTR2CHTR2AHTR2BCYP19A1DRD2 | |
| SCHEMBL31525384 | 0.85 | HTR2C (0.64) | HTR2CHTR2AHTR2BCYP19A1DRD2 | |
| SCHEMBL6937686 | 0.82 | HTR2A (0.54) | HTR2CHTR2AHTR2BCYP19A1CYP11B1 | |
| SCHEMBL2463469 | 0.80 | ACHE (0.60) | HTR2CHTR2AHTR2BCYP19A1CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185525-B1 | PYRAZOLE 3,5 CARBOXYLATE DERIVATIVES PREPARATION AND THERAPEUTIC APPLICATION THEREOF | SANOFI SA (FR) | 2016-12-14 | — | — | EP | disclosed |
| US-9102628-B2 | Derivatives of pyrazole 3,5-carboxylates, their preparation and their application in therapeutics | SANOFI (FR) | 2015-08-11 | — | — | US | disclosed |
| US-9102628-B2 | Derivatives of pyrazole 3,5-carboxylates, their preparation and their application in therapeutics | SANOFI (FR) | 2015-08-11 | — | — | US | disclosed |
| US-20100160377-A1 | DERIVATIVES OF PYRAZOLE 3,5-CARBOXYLATES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | US | disclosed |
| US-20100160377-A1 | DERIVATIVES OF PYRAZOLE 3,5-CARBOXYLATES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI-AVENTIS (FR) | 2010-06-24 | — | — | US | disclosed |
| EP-2098519-A1 | Process for the synthesis of ramelteon and its intermediates | Teva Pharmaceutical Industries Ltd. (IL) | 2009-09-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160377-A1 | DERIVATIVES OF PYRAZOLE 3,5-CARBOXYLATES, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | CYP3A5, ADH5, AVPR2 | HTR2C 1355/4885HTR2A 3029/4885HTR2B 2547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.